Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Parsley, H. Masamune, W. Hoye, N. Kadrichu, A. Hussaini, L. Rubin, M. Gladwin, M. Mancini (San Diego, Baltimore, , San Carlos, United States Of America). Selection of the optimal nebulizer for further clinical development of inhaled nebulized nitrite (AIR001) in pulmonary arterial hypertension patients. Eur Respir J 2012; 40: Suppl. 56, 1509

Member's Comments

No comment yet.

Related content which might interest you: The influence of heated heliox-driven nebulizer therapy on pulmonary hypertension and arterial oxygenation of patients with bronchial asthma Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Acute response of iloprost inhalation using the Breelib nebulizer in pulmonary arterial hypertension: the Breelib acute study Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension Source: Eur Respir J 2001; 17: 14-19 Year: 2001 Effects of long-acting inhaled β-adrenergic and anticholinergic drugs on respiratory function and arterial blood gases in patients with COPD Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006 Effects of inhaled salbutamol in primary pulmonary hypertension Source: Eur Respir J 2002; 20: 524-528 Year: 2002 Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 323s Year: 2001 Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Experience with inhaled iloprost in paediatric pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Inhaled iloprost for the treatment of pulmonary hypertension Source: Eur Respir Rev 2009; 18: 29-34 Year: 2009 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Oral sildenafil is a potent pulmonary vasodilator and improves gas exchange in patients with COPD with pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003 Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 VENTASWITCH study: Switching from Ventavis (iloprost) V10 to V20 improves inhalation behaviour in patients with pulmonary arterial hypertension (PAH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Influence of inhaled iloprost on transpulmonary gradient of big-endothelin in patients with pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 25s Year: 2002 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Acetylene single breath estimation of effective pulmonary blood flow in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 423s Year: 2006 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017